 |
인쇄하기
취소
|
Sanofi starts Phase III clinical trial for efpeglenatide exported from Hanmi Pharm
A Phase III clinical trial for ‘efpeglenatide’ developed by Hanmi Pharm on its own and whose technology was transferred to Sanofi, a global pharmaceutical company, will start on 4 December.
On the 28th(local Korea time), ClinicalTrials, a global clinical trial information website, updated contents of the Phase III clinical trial for efpeglenatide on 400 hepatitis B type B patients.
Efpeglenat...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.